Travere Therapeutics (TVTX) Competitors $14.84 +0.13 (+0.88%) Closing price 04:00 PM EasternExtended Trading$14.95 +0.11 (+0.77%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACADShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics PTC Therapeutics Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Zai Lab ACADIA Pharmaceuticals Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Is AXSM or TVTX more profitable? Axsome Therapeutics has a net margin of -64.39% compared to Travere Therapeutics' net margin of -82.88%. Axsome Therapeutics' return on equity of -272.80% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-64.39% -272.80% -36.69% Travere Therapeutics -82.88%-1,179.73%-41.10% Does the media refer more to AXSM or TVTX? In the previous week, Travere Therapeutics had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 8 mentions for Travere Therapeutics and 6 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.80 beat Travere Therapeutics' score of 0.42 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AXSM or TVTX? Axsome Therapeutics presently has a consensus target price of $172.33, suggesting a potential upside of 65.85%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 116.60%. Given Travere Therapeutics' higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87 Which has stronger earnings and valuation, AXSM or TVTX? Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$385.69M13.27-$287.22M-$5.77-18.01Travere Therapeutics$233.18M5.65-$321.55M-$2.81-5.28 Which has more risk and volatility, AXSM or TVTX? Axsome Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Do institutionals and insiders have more ownership in AXSM or TVTX? 81.5% of Axsome Therapeutics shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.1% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAxsome Therapeutics beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-5.2821.2626.2019.89Price / Sales5.65279.34415.50166.23Price / CashN/A41.8936.4957.06Price / Book19.537.508.055.39Net Income-$321.55M-$55.05M$3.15B$248.50M7 Day Performance-0.67%2.49%1.92%2.96%1 Month Performance-4.38%7.40%4.90%6.02%1 Year Performance83.44%5.42%35.95%20.44% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics3.1806 of 5 stars$14.84+0.9%$32.14+116.6%+77.7%$1.32B$233.18M-5.28460Analyst ForecastAXSMAxsome Therapeutics4.6726 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$4.96B$385.69M-17.62380Analyst RevisionAKROAkero Therapeutics3.6155 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.32BN/A-27.7130PCVXVaxcyte1.7882 of 5 stars$33.25+1.2%$136.50+310.5%-57.2%$4.24BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.0895 of 5 stars$17.87+0.7%$27.67+54.8%+54.8%$4.24B$426.45M21.02530PTCTPTC Therapeutics4.4113 of 5 stars$49.60-1.2%$65.00+31.0%+55.9%$3.98B$806.78M7.621,410Analyst RevisionGap DownRYTMRhythm Pharmaceuticals3.8956 of 5 stars$62.13+0.2%$76.62+23.3%+53.4%$3.94B$130.13M-22.11140CYTKCytokinetics4.2833 of 5 stars$32.64+0.6%$70.92+117.3%-38.5%$3.87B$18.47M-6.17250Positive NewsKRYSKrystal Biotech4.6181 of 5 stars$137.92+4.1%$211.13+53.1%-23.7%$3.83B$290.52M33.15210Analyst RevisionHigh Trading VolumeZLABZai Lab3.3837 of 5 stars$36.01+4.2%$47.37+31.5%+103.4%$3.81B$398.99M-14.461,869Analyst ForecastInsider TradeAnalyst RevisionACADACADIA Pharmaceuticals4.6866 of 5 stars$22.48-1.0%$27.64+23.0%+33.2%$3.80B$957.80M16.41510 Related Companies and Tools Related Companies Axsome Therapeutics Competitors Akero Therapeutics Competitors Vaxcyte Competitors ADMA Biologics Competitors PTC Therapeutics Competitors Rhythm Pharmaceuticals Competitors Cytokinetics Competitors Krystal Biotech Competitors Zai Lab Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts